REFERENCES
2. Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10-45.
3. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913-21.
4. Koltai T, Reshkin SJ, Carvalho TMA, et al. Resistance to gemcitabine in pancreatic ductal adenocarcinoma: a physiopathologic and pharmacologic review. Cancers. 2022;14:2486.
5. Mannucci A, Goel A. Advances in pancreatic cancer early diagnosis, prevention, and treatment: the past, the present, and the future. CA Cancer J Clin. 2026;76:e70035.
6. Gao J, Wang J, Guan C, et al. Advances in drug therapy for metastatic pancreatic ductal adenocarcinoma. J Cancer. 2024;15:2214-28.
7. Singh NK, Ahmad F, Husain A. Molecular dissection of pancreatic cancer signaling: toward targeted therapies for KRAS, MDM2-TP53, EGFR, and PI3K/AKT/mTOR. Pathol Res Pract. 2026;283:156506.
8. Kumar S, Singh SK, Srivastava P, Suresh S, Rana B, Rana A. Interplay between MAP kinases and tumor microenvironment: opportunity for immunotherapy in pancreatic cancer. Adv Cancer Res. 2023;159:113-43.
9. Ghanwatkar Y, Ramanathan R, Mahato RI. Desmoplasia and therapeutic resistance in pancreatic ductal adenocarcinoma. Cancer Lett. 2026;654:218618.
10. Zhou J, Li J, Lu H, Hong Y. Deciphering the secrets of tumor-initiating cells in pancreatic ductal adenocarcinoma microenvironment: mechanisms and therapeutic opportunities. Front Immunol. 2025;16:1614707.
11. Sharma R, Malviya R. Correlation between hypoxia and HGF/c-MET expression in the management of pancreatic cancer. Biochim Biophys Acta Rev Cancer. 2023;1878:188869.
12. Suresh DS, Salcedo-Noriega MF, Vaish U, et al. Cytokine circuitry in pancreatic cancer: targets for overcoming immune checkpoint inhibitor resistance in PDAC. Cytokine Growth Factor Rev. 2026;88:124-37.
13. Zhao K, Xiao MM, Yang YS, Xiao X. Tumor microenvironment phenotyping guides precision therapy in unresectable pancreatic cancer. World J Gastrointest Oncol. 2025;17:109830.
14. Zhang P, Pan J, Lin S, et al. Smart drug delivery platforms reprogramming cancer immune cycle to mitigate immune resistance of pancreatic tumors. Adv Drug Deliv Rev. 2025;224:115620.
15. Sherman MH, Beatty GL. Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance. Annu Rev Pathol. 2023;18:123-48.
16. Ju Y, Xu D, Liao MM, et al. Barriers and opportunities in pancreatic cancer immunotherapy. NPJ Precis Oncol. 2024;8:199.
17. Qi H, Lv G, Zhang S, Xue R, Liu M. Unraveling pancreatic ductal adenocarcinoma at single-cell resolution with spatial insights: from mechanisms to clinical translation. Cancer Lett. 2026;645:218391.
18. Werba G, Weissinger D, Kawaler EA, et al. Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment. Nat Commun. 2023;14:797.
19. Chen MM, Gao Q, Ning H, et al. Integrated single-cell and spatial transcriptomics uncover distinct cellular subtypes involved in neural invasion in pancreatic cancer. Cancer Cell. 2025;43:1656-76.e10.
20. Mao X, Xu J, Wang W, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20:131.
21. Yu X, Yang J, Xu J, et al. Histone lactylation: from tumor lactate metabolism to epigenetic regulation. Int J Biol Sci. 2024;20:1833-54.
22. Yan J, Ou H, Wang S, Jin K, Yu X, Wu W. Overcoming multidimensional immunotherapy resistance in PDAC: from microenvironment to clinic. Front Immunol. 2026;17:1782960.
23. Shi J, Cui X, Wang J, Liu G, Meng J, Zhang Y. Crosstalk between the tumor immune microenvironment and metabolic reprogramming in pancreatic cancer: new frontiers in immunotherapy. Front Immunol. 2025;16:1564603.
24. Kung HC, Zheng KW, Zimmerman JW, Zheng L. The tumour microenvironment in pancreatic cancer - new clinical challenges, but more opportunities. Nat Rev Clin Oncol. 2025;22:969-95.
25. Espona-Fiedler M, Patthey C, Lindblad S, Sarró I, Öhlund D. Overcoming therapy resistance in pancreatic cancer: new insights and future directions. Biochem Pharmacol. 2024;229:116492.
26. Saúde-Conde R, Arçay Öztürk A, Stosic K, et al. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma or a metaphor for heterogeneity: from single-cell analysis to whole-body imaging. Biomedicines. 2024;12:591.
27. Sato H, Hara T, Meng S, et al. Multifaced roles of desmoplastic reaction and fibrosis in pancreatic cancer progression: current understanding and future directions. Cancer Sci. 2023;114:3487-95.
28. Sigirli S, Karakas D. Fibrotic fortresses and therapeutic frontiers: pancreatic stellate cells and the extracellular matrix in pancreatic cancer. Cancer Med. 2025;14:e70788.
29. Liu X, Shao Y, Li Y, et al. Extensive review of nanomedicine strategies targeting the tumor microenvironment in PDAC. Int J Nanomedicine. 2025;20:3379-406.
30. Gong P, Wang F, Hua Y, Ying J, Chen J, Qiao Y. Collagenase-mediated extracellular matrix targeting for enhanced drug penetration and therapeutic efficacy in nanoscale delivery systems for cancer therapy. J Nanobiotechnology. 2025;23:733.
31. Wang D, Li Y, Ge H, Ghadban T, Reeh M, Güngör C. The extracellular matrix: a key accomplice of cancer stem cell migration, metastasis formation, and drug resistance in PDAC. Cancers. 2022;14:3998.
32. Detert K, Piotrowsky A, Marongiu L, et al. Progress and challenges in the development of advanced pancreatic cancer organoids. J Exp Clin Cancer Res. 2026;45:113.
33. Urbanova M, Cihova M, Buocikova V, et al. Nanomedicine and epigenetics: new alliances to increase the odds in pancreatic cancer survival. Biomed Pharmacother. 2023;165:115179.
34. Cai W, Chen Y, Dai S, Zhao J, Chen L. Hyaluronic acid and its role in pancreatic cancer: mechanisms of tumor progression, drug resistance, and therapeutic targeting. Pharmacol Res. 2025;221:107958.
35. Guo Z, Ashrafizadeh M, Zhang W, Zou R, Sethi G, Zhang X. Molecular profile of metastasis, cell plasticity and EMT in pancreatic cancer: a pre-clinical connection to aggressiveness and drug resistance. Cancer Metastasis Rev. 2024;43:29-53.
36. Hamada S, Matsumoto R, Masamune A. Pancreatic stellate cells and metabolic alteration: physiology and pathophysiology. Front Physiol. 2022;13:865105.
37. Ando R, Sakai A, Iida T, Kataoka K, Mizutani Y, Enomoto A. Good and bad stroma in pancreatic cancer: relevance of functional states of cancer-associated fibroblasts. Cancers. 2022;14:3315.
38. Menezes S, Okail MH, Jalil SMA, Kocher HM, Cameron AJM. Cancer-associated fibroblasts in pancreatic cancer: new subtypes, new markers, new targets. J Pathol. 2022;257:526-44.
39. Zhang Q, Cao Z, Yan S, et al. Metabolic and immune crosstalk between cancer-associated fibroblasts and pancreatic cancer cells. J Transl Med. 2025;23:1118.
40. Wu J, Dai T, Li Z, et al. Integrating multi-modal transcriptomics identifies cellular subtypes with distinct roles in PDAC progression. Cell Oncol. 2025;48:1571-92.
41. Biffi G, Tuveson DA. Diversity and biology of cancer-associated fibroblasts. Physiol Rev. 2021;101:147-76.
42. Krishnamurty AT, Shyer JA, Thai M, et al. LRRC15+ myofibroblasts dictate the stromal setpoint to suppress tumour immunity. Nature. 2022;611:148-54.
43. Zhang T, Ren Y, Yang P, Wang J, Zhou H. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. Cell Death Dis. 2022;13:897.
44. Limbu KR, Chhetri RB, Oh YS, Oak MH, Beak DJ, Park EY. Oxidative stress and pancreatic cancer: a dual role in tumorigenesis and drug toxicity. Toxicol Res. 2025;41:533-51.
45. Grobbelaar C, Kgomo M, Mabeta P. Angiogenesis and pancreatic cancer: novel approaches to overcome treatment resistance. Curr Cancer Drug Targets. 2024;24:1116-27.
46. Mosalem OM, Abdelhakeem A, Abdel-Razeq NH, Babiker H. Pancreatic ductal adenocarcinoma (PDAC): clinical progress in the last five years. Expert Opin Investig Drugs. 2025;34:149-60.
47. Hsu SK, Jadhao M, Liao WT, Chang WT, Hung CT, Chiu CC. Culprits of PDAC resistance to gemcitabine and immune checkpoint inhibitor: tumour microenvironment components. Front Mol Biosci. 2022;9:1020888.
48. Yao H, Luo L, Li R, et al. New insight into the role of SMAD4 mutation/deficiency in the prognosis and therapeutic resistance of pancreatic ductal adenocarcinomas. Biochim Biophys Acta Rev Cancer. 2024;1879:189220.
49. Song N, Cui K, Zeng L, et al. Advance in the role of chemokines/chemokine receptors in carcinogenesis: focus on pancreatic cancer. Eur J Pharmacol. 2024;967:176357.
50. Xu J, Yao H, Wang J, et al. Perineural invasion and the “cold” tumor microenvironment in pancreatic cancer: mechanisms of crosstalk and therapeutic opportunities. Front Immunol. 2025;16:1650117.
51. Guo X, Zhang H, Yao L, Ma W. Harnessing the effector-to-regulatory T cell ratio to advance prognosis and precision therapy in pancreatic cancer. Crit Rev Oncol Hematol. 2026;218:105076.
52. Pan D, Li X, Qiao X, Wang Q. Immunosuppressive tumor microenvironment in pancreatic cancer: mechanisms and therapeutic targets. Front Immunol. 2025;16:1582305.
53. Kemp SB, Pasca di Magliano M, Crawford HC. Myeloid cell mediated immune suppression in pancreatic cancer. Cell Mol Gastroenterol Hepatol. 2021;12:1531-42.
54. Jiang S, Ren B, Ding C, et al. Polyamines in pancreatic cancer: reshaping the immunosuppressive tumor microenvironment. Cancer Lett. 2025;633:218016.
55. Weizman N, Krelin Y, Shabtay-Orbach A, et al. Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase. Oncogene. 2014;33:3812-9.
56. Halbrook CJ, Pontious C, Kovalenko I, et al. Macrophage-released pyrimidines inhibit gemcitabine therapy in pancreatic cancer. Cell Metab. 2019;29:1390-9.e6.
57. D’Errico G, Alonso-Nocelo M, Vallespinos M, et al. Tumor-associated macrophage-secreted 14-3-3ζ signals via AXL to promote pancreatic cancer chemoresistance. Oncogene. 2019;38:5469-85.
58. Rohila D, Park IH, Pham TV, et al. Syk inhibition reprograms tumor-associated macrophages and overcomes gemcitabine-induced immunosuppression in pancreatic ductal adenocarcinoma. Cancer Res. 2023;83:2675-89.
59. Nywening TM, Belt BA, Cullinan DR, et al. Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma. Gut. 2018;67:1112-23.
60. Peng L, Liang Y, Guo X, et al. Nanomedicine breakthroughs overcoming pancreatic cancer drug resistance through precision nano-interventions. Nanoscale Adv. 2025;7:5888-904.
61. Velasco RM, García AG, Sánchez PJ, Sellart IM, Sánchez-Arévalo Lobo VJ. Tumour microenvironment and heterotypic interactions in pancreatic cancer. J Physiol Biochem. 2023;79:179-92.
62. Lin HJ, Liu Y, Caroland K, Lin J. Polarization of cancer-associated macrophages maneuver neoplastic attributes of pancreatic ductal adenocarcinoma. Cancers. 2023;15:3507.
63. Salehi-Sangani P, Maharati AH, Payami B, Aliakbarian M, Abbaszadegan MR. HypoxamiRs in pancreatic cancer: master regulators of the hypoxic tumor microenvironment. Cell Biol Toxicol. 2025;41:146.
64. Tao J, Yang G, Zhou W, et al. Targeting hypoxic tumor microenvironment in pancreatic cancer. J Hematol Oncol. 2021;14:14.
65. Hao X, Ren Y, Feng M, Wang Q, Wang Y. Metabolic reprogramming due to hypoxia in pancreatic cancer: implications for tumor formation, immunity, and more. Biomed Pharmacother. 2021;141:111798.
66. Gan L, Luo P, Zou J, et al. Crosstalk between hypoxia-inducible factor (HIF) and lncRNAs in digestive tumors: from molecular mechanisms to clinical translation. Front Cell Dev Biol. 2025;13:1611889.
67. Toledo B, Deiana C, Scianò F, et al. Treatment resistance in pancreatic and biliary tract cancer: molecular and clinical pharmacology perspectives. Expert Rev Clin Pharmacol. 2024;17:323-47.
68. Chung WC, Xu K. Notch signaling pathway in pancreatic tumorigenesis. Adv Cancer Res. 2023;159:1-36.
69. Palamaris K, Felekouras E, Sakellariou S. Epithelial to mesenchymal transition: key regulator of pancreatic ductal adenocarcinoma progression and chemoresistance. Cancers. 2021;13:5532.
70. da Silva VP, Mesquita CB, Nunes JS, de Bem Prunes B, Rados PV, Visioli F. Effects of extracellular acidity on resistance to chemotherapy treatment: a systematic review. Med Oncol. 2018;35:161.
71. Stigliani A, Ialchina R, Yao J, et al. Adaptation to an acid microenvironment promotes pancreatic cancer organoid growth and drug resistance. Cell Rep. 2024;43:114409.
72. Cappellesso F, Orban MP, Shirgaonkar N, et al. Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression and immunotherapy resistance in pancreatic cancer. Nat Cancer. 2022;3:1464-83.
73. Zhang J, Kong X, Zhou B, et al. Metabolic reprogramming of drug resistance in pancreatic cancer: mechanisms and effects. Mol Aspects Med. 2025;103:101368.
74. Zuzčák M, Trnka J. Cellular metabolism in pancreatic cancer as a tool for prognosis and treatment (Review). Int J Oncol. 2022;61:93.
75. Tuerhong A, Xu J, Shi S, et al. Overcoming chemoresistance by targeting reprogrammed metabolism: the Achilles’ heel of pancreatic ductal adenocarcinoma. Cell Mol Life Sci. 2021;78:5505-26.
76. Li X, Zhou J, Wang X, et al. Pancreatic cancer and fibrosis: targeting metabolic reprogramming and crosstalk of cancer-associated fibroblasts in the tumor microenvironment. Front Immunol. 2023;14:1152312.
77. Zhao Z, Mei Y, Wang Z, He W. The effect of oxidative phosphorylation on cancer drug resistance. Cancers. 2022;15:62.
78. Ma J, Bhardwaj V, Lobie PE, Pandey V. Metabolic plasticity in pancreatic ductal adenocarcinoma progression and response to treatment. Mol Cancer. 2026;25:108.
79. Fang L, Gao D, Jiang Z, Li G, Li M. Glutamine’s double-edged sword: fueling tumor growth and offering therapeutic hope. Front Immunol. 2025;16:1578940.
80. Zhang Y, Yang Z, Liu Y, Pei J, Li R, Yang Y. Targeting lipid metabolism: novel insights and therapeutic advances in pancreatic cancer treatment. Lipids Health Dis. 2025;24:12.
81. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367:eaau6977.
82. Binenbaum Y, Fridman E, Yaari Z, et al. Transfer of miRNA in macrophage-derived exosomes induces drug resistance in pancreatic adenocarcinoma. Cancer Res. 2018;78:5287-99.
83. Xavier CPR, Castro I, Caires HR, et al. Chitinase 3-like-1 and fibronectin in the cargo of extracellular vesicles shed by human macrophages influence pancreatic cancer cellular response to gemcitabine. Cancer Lett. 2021;501:210-23.
84. Zheng S, Tian Q, Yuan Y, et al. Extracellular vesicle-packaged circBIRC6 from cancer-associated fibroblasts induce platinum resistance via SUMOylation modulation in pancreatic cancer. J Exp Clin Cancer Res. 2023;42:324.
85. Yu M, Su M, Tian Z, et al. Extracellular vesicle-packaged linc-ZNF25-1 from pancreatic cancer cell promotes pancreatic stellate cell uptake of asparagine to advance chemoresistance. Adv Sci. 2025;12:e2413439.
86. Patel GK, Khan MA, Zubair H, et al. Comparative analysis of exosome isolation methods using culture supernatant for optimum yield, purity and downstream applications. Sci Rep. 2019;9:5335.
87. Capula M, Perán M, Xu G, et al. Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance. Drug Resist Updat. 2022;64:100864.
88. Bautista J, Bedón-Galarza R, Martínez-Hidalgo F, et al. Decoding the microbial blueprint of pancreatic cancer. Front Med. 2026;13:1737582.
89. Zheng SH, Li KZ, Feng G, et al. Gut microbiota reshaping the pancreatic cancer immune microenvironment: new avenues for immunotherapy. Mol Cancer. 2025;24:313.
90. Guo Z, Liu Q. Dual role of exosomes in pancreatic cancer: underlying mechanisms and research advances (Review). Oncol Lett. 2026;31:192.
91. Carretero-Fernández M, Ruíz-Durán L, Uysal-Onganer P, et al. Non-coding RNAs as biomarkers and therapeutic targets in pancreatic cancer: clinical implications and translational perspectives. Biomed Pharmacother. 2026;199:119394.
92. Wu Y, Jiang X, Yu Z, Xing Z, Ma Y, Qing H. Mechanisms of anti-PD therapy resistance in digestive system neoplasms. Recent Pat Anticancer Drug Discov. 2025;20:1-25.
93. Liu Y, Dai Y, Wang L. Spatial omics at the forefront: emerging technologies, analytical innovations, and clinical applications. Cancer Cell. 2026;44:24-49.
94. Malchiodi ZX, Lekan AA, Suter RK, et al. Periductal fibroblast density defines lymphocyte exclusion via a CD44-dependent stromal checkpoint in pancreatic cancer. Cancer Immunol Res. 2026;14:1538-52.
95. Zhang Z, Zhang H, Liu T, Chen T, Wang D, Tang D. Heterogeneous pancreatic stellate cells are powerful contributors to the malignant progression of pancreatic cancer. Front Cell Dev Biol. 2021;9:783617.
96. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1:313-23.
98. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67:1030-7.
99. Phi LTH, Sari IN, Yang YG, et al. Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem Cells Int. 2018;2018:5416923.
100. Sancho P, Burgos-Ramos E, Tavera A, et al. MYC/PGC-1α balance determines the metabolic phenotype and plasticity of pancreatic cancer stem cells. Cell Metab. 2015;22:590-605.
101. Yang S, Kimmelman AC. A critical role for autophagy in pancreatic cancer. Autophagy. 2011;7:912-3.
102. Yang A, Rajeshkumar NV, Wang X, et al. Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations. Cancer Discov. 2014;4:905-13.
103. Rausch V, Liu L, Apel A, et al. Autophagy mediates survival of pancreatic tumour-initiating cells in a hypoxic microenvironment. J Pathol. 2012;227:325-35.
104. Sousa CM, Biancur DE, Wang X, et al. Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature. 2016;536:479-83.
105. Kinsey CG, Camolotto SA, Boespflug AM, et al. Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nat Med. 2019;25:620-7.
106. Nazio F, Bordi M, Cianfanelli V, Locatelli F, Cecconi F. Autophagy and cancer stem cells: molecular mechanisms and therapeutic applications. Cell Death Differ. 2019;26:690-702.
107. Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060-72.
108. Zhang C, Liu X, Jin S, Chen Y, Guo R. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol Cancer. 2022;21:47.
109. Badgley MA, Kremer DM, Maurer HC, et al. Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science. 2020;368:85-9.
110. Dai E, Han L, Liu J, et al. Ferroptotic damage promotes pancreatic tumorigenesis through a TMEM173/STING-dependent DNA sensor pathway. Nat Commun. 2020;11:6339.
111. Cui K, Wang K, Huang Z. Ferroptosis and the tumor microenvironment. J Exp Clin Cancer Res. 2024;43:315.
112. Lei G, Zhuang L, Gan B. The roles of ferroptosis in cancer: tumor suppression, tumor microenvironment, and therapeutic interventions. Cancer Cell. 2024;42:513-34.
113. Lu L, Johnson CH, Khan SA, Irwin ML. GDF15 in the tumor microenvironment: a central mediator of cancer immunometabolism and therapeutic resistance. Cytokine Growth Factor Rev. 2026;88:47-57.
114. Sun K, Zhang X, Shi J, et al. Elevated protein lactylation promotes immunosuppressive microenvironment and therapeutic resistance in pancreatic ductal adenocarcinoma. J Clin Invest. 2025;135:e187024.
115. King RJ, Shukla SK, He C, et al. CD73 induces GM-CSF/MDSC-mediated suppression of T cells to accelerate pancreatic cancer pathogenesis. Oncogene. 2022;41:971-82.
116. Tang T, Huang X, Lu M, Zhang G, Han X, Liang T. Transcriptional control of pancreatic cancer immunosuppression by metabolic enzyme CD73 in a tumor-autonomous and -autocrine manner. Nat Commun. 2023;14:3364.
117. Ala M. The footprint of kynurenine pathway in every cancer: a new target for chemotherapy. Eur J Pharmacol. 2021;896:173921.
118. Peng M, Ying Y, Zhang Z, Liu L, Wang W. Reshaping the pancreatic cancer microenvironment at different stages with chemotherapy. Cancers. 2023;15:2448.
119. Bruciamacchie M, Garambois V, Vie N, et al. ATR inhibition potentiates FOLFIRINOX cytotoxic effect in models of pancreatic ductal adenocarcinoma by remodelling the tumour microenvironment. Br J Cancer. 2025;132:222-35.
120. Liu X, Baer JM, Stone ML, et al. Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy. Sci Transl Med. 2024;16:eado2402.
121. Lian M, Mortoglou M, Uysal-Onganer P. Impact of hypoxia-induced miR-210 on pancreatic cancer. Curr Issues Mol Biol. 2023;45:9778-92.
122. Ala M. Noncoding ribonucleic acids (RNAs) may improve response to immunotherapy in pancreatic cancer. ACS Pharmacol Transl Sci. 2024;7:2557-72.
123. Otieno MO, Powrózek T, Garcia-Foncillas J, Martinez-Useros J. The crosstalk within tumor microenvironment and exosomes in pancreatic cancer. Biochim Biophys Acta Rev Cancer. 2025;1880:189308.
124. Kumarasamy V, Wang J, Frangou C, et al. The extracellular niche and tumor microenvironment enhance KRAS inhibitor efficacy in pancreatic cancer. Cancer Res. 2024;84:1115-32.
125. Ye X, Yu Y, Zheng X, Ma H. Clinical immunotherapy in pancreatic cancer. Cancer Immunol Immunother. 2024;73:64.
126. Liu J, Zhang B, Huang B, et al. A stumbling block in pancreatic cancer treatment: drug resistance signaling networks. Front Cell Dev Biol. 2024;12:1462808.
127. Tao X, Go V, Xiao GG. Progress on the role of reactive oxygen species-mediated tumor microenvironment in pancreatic cancer. Acta Physiol Sin. 2021;73:197-207.
128. Jang JE, Hajdu CH, Liot C, Miller G, Dustin ML, Bar-Sagi D. Crosstalk between regulatory T cells and tumor-associated dendritic cells negates anti-tumor immunity in pancreatic cancer. Cell Rep. 2017;20:558-71.
129. Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities. Nat Rev Clin Oncol. 2020;17:527-40.
130. Barker HE, Paget JT, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015;15:409-25.
131. Jing X, Yang F, Shao C, et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 2019;18:157.
133. Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J. Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol. 2012;9:674-87.
134. Lander VE, Belle JI, Kingston NL, et al. Stromal reprogramming by FAK inhibition overcomes radiation resistance to allow for immune priming and response to checkpoint blockade. Cancer Discov. 2022;12:2774-99.
135. Nair ST, Abhi C, Kamalasanan K, et al. Pathophysiology-driven approaches for overcoming nanomedicine resistance in pancreatic cancer. Mol Pharm. 2024;21:5960-88.
136. Van Cutsem E, Tempero MA, Sigal D, et al.; HALO 109-301 Investigators. Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma. J Clin Oncol. 2020;38:3185-94.
137. Perez KJ, Dias Costa A, Jordan A, et al. Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial. Nat Cancer. 2026;7:928-43.
138. Easty D, McDermott R, Murphy AG, et al. Early termination of NCT04617067, a phase II, open label, clinical trial of oral paricalcitol in combination with gemcitabine and NAB-paclitaxel therapy in advanced pancreatic cancer. BMC Cancer. 2026;26:255.
139. Nywening TM, Wang-Gillam A, Sanford DE, et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 2016;17:651-62.
140. Noel M, O’Reilly EM, Wolpin BM, et al. Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. Invest New Drugs. 2020;38:800-11.
141. Bever KM, Shin SM, Durham JN, et al. A phase 2 trial of CXCR4 antagonism and PD1 inhibition in metastatic pancreatic adenocarcinoma reveals recruitment of T cells but also immunosuppressive macrophages. Oncoimmunology. 2025;14:2543614.
142. Coveler AL, Reilley MJ, Zalupski M, et al. A phase Ib/II randomized clinical trial of oleclumab with or without durvalumab plus chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma. Clin Cancer Res. 2024;30:4609-17.
143. Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;331:1612-6.
144. Strickler JH, Satake H, George TJ, et al. Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer. N Engl J Med. 2023;388:33-43.
145. Mahadevan KK, McAndrews KM, LeBleu VS, et al. KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells. Cancer Cell. 2023;41:1606-20.e8.
146. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21:418-29.
147. Sherman MH, Yu RT, Engle DD, et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell. 2014;159:80-93.
148. Özdemir BC, Pentcheva-Hoang T, Carstens JL, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014;25:719-34.
149. Rhim AD, Oberstein PE, Thomas DH, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014;25:735-47.
150. Johansen AM, Forsythe SD, McGrath CT, et al. TGFβ in pancreas and colorectal cancer: opportunities to overcome therapeutic resistance. Clin Cancer Res. 2024;30:3676-87.
151. Pothula SP, Xu Z, Goldstein D, Pirola RC, Wilson JS, Apte MV. Targeting HGF/c-MET axis in pancreatic cancer. Int J Mol Sci. 2020;21:9170.
152. Melisi D, Oh DY, Hollebecque A, et al. Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. J Immunother Cancer. 2021;9:e002068.
153. Lorestani P, Dashti M, Nejati N, et al. The complex role of macrophages in pancreatic cancer tumor microenvironment: a review on cancer progression and potential therapeutic targets. Discov Oncol. 2024;15:369.
154. Liang L, Wang W. The impact of p53 mutation on tumor immune evasion: mechanistic insights and clinical implications. Front Immunol. 2026;17:1753215.
155. Xu M, Zhao X, Wen T, Qu X. Unveiling the role of KRAS in tumor immune microenvironment. Biomed Pharmacother. 2024;171:116058.
156. Liu X, Ding Q, Zhang H, Zhang X, Chen Q, Weng S. The CD39-CD73-adenosine axis: master regulator of immune evasion and therapeutic target in pancreatic ductal adenocarcinoma. Biochim Biophys Acta Rev Cancer. 2025;1880:189443.
157. Abou Khouzam R, Lehn JM, Mayr H, et al. Hypoxia, a targetable culprit to counter pancreatic cancer resistance to therapy. Cancers. 2023;15:1235.
158. McDonald PC, Winum JY, Supuran CT, Dedhar S. Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget. 2012;3:84-97.
159. Borad MJ, Reddy SG, Bahary N, et al. Randomized phase II trial of gemcitabine plus TH-302 versus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2015;33:1475-81.
160. Mayer A, Vaupel P. Hypoxia, lactate accumulation, and acidosis: siblings or accomplices driving tumor progression and resistance to therapy? Adv Exp Med Biol. 2013;789:203-9.
161. Guillaumond F, Leca J, Olivares O, et al. Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. Proc Natl Acad Sci U S A. 2013;110:3919-24.
162. Beatty GL, Werba G, Lyssiotis CA, Simeone DM. The biological underpinnings of therapeutic resistance in pancreatic cancer. Genes Dev. 2021;35:940-62.
163. A phase 1b/2a study of gemcitabine and nab-paclitaxel in combination with avutometinib (VS-6766) and defactinib in patients with previously untreated metastatic adenocarcinoma of the pancreas. 2022. Available from: https://clinicaltrials.gov/study/NCT05669482. [Last accessed on 13 Oct 2026].
164. Lim KH, Spencer KR, Safyan RA, et al. Avutometinib/defactinib and gemcitabine/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: initial safety and efficacy of phase 1b/2 study (RAMP 205). J Clin Oncol. 2024;42:4140.
165. Phase II study of stereotactic body radiotherapy and focal adhesion kinase inhibitor in advanced pancreas adenocarcinoma. 2020. Available from: https://clinicaltrials.gov/study/NCT04331041. [Last accessed on 13 Oct 2026].
166. Jacobetz MA, Chan DS, Neesse A, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 2013;62:112-20.
